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The treatment of CML at an environment with
limited resources
David Gómez-Almaguer1, Olga G. Cantú-Rodríguez1, Cesar H. Gutiérrez-Aguirre1,
Guillermo J. Ruiz-Argüelles2
1Hematology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo
León, Monterrey, NL, Mexico, 2Centro de Hematología y Medicina Interna de Puebla, Clínica Ruiz, Puebla,
México
Objectives: This article reviews clinical experiences in the treatment of chronic myeloid leukemia (CML) in an
environment of limited resources.
Methods:We reviewed recent publications on Pub med and abstracts from mayor congresses relevant to the
disease.
Results: CML is a hematological neoplasm observed more frequently in adults, regardless of their
socioeconomic status. Until recently, available treatments improved patients’ quality of life but did not
modify survival. It was not until interferon appeared that patients received a drug that reduced and even
eliminated Philadelphia chromosome-positive (Ph+) cells.
Discussion: With the start of the new millennium, the International Randomized Study of Interferon-α plus
cytarabine versus STI571 (IRIS) trial demonstrated a dramatic improvement in survival by comparing
imatinib versus interferon alpha plus cytarabine. The Food and Drug Administration (FDA) approved
imatinib as first-line treatment for newly diagnosed CML in 2001 due to its outstanding effectiveness.
Years later, three second-generation (dasatinib, nilotinib, bosutinib) and one third-generation (ponatinib)
tyrosine-kinase inhibitors (TKIs) were developed and approved. These highly effective treatment options,
however, are not affordable for many low-income patients. Additionally, the use of drugs that effectively
treat but do not cure the disease has resulted in an important economic impact for patients and health
care systems worldwide, especially those in developing countries. Imatinib is the least expensive and a
very effective TKI in many low-income countries. Early allogeneic stem cell transplantation must be
considered in the management of selected patients before CML transformation.
Keywords:Chronic myeloid leukemia, Imatinib, Low-income, Generic, Allogeneic stem cell transplantation, Complete cytogenetic remission, Nilotinib, FISH
Introduction
Before the year 2000, chronic myeloid leukemia
(CML) treatment was based on the use of busulfan,
hydroxyurea, and interferon alpha.1 At that time, the
treatment with the highest potential for disease-free
survival and cure was allogeneic stem cell transplan-
tation (Allo-SCT); however, this procedure was not
free of important morbidity and mortality, and thus
was reserved for younger patients with an human leu-
kocyte antigen-identical related donor. Imatinib mesy-
late changed the panorama for CML.2 In most cases, a
high response rate with prolonged survival can be
obtained. Transformation to accelerated or blast
phase has been reduced to 1–1.5% per year, compared
to over 20% in the pre-imatinib era.3 However, achiev-
ing these results depends on continuous drug intake.
The use of an expensive drug, which effectively treats
but does not cure the disease, has increased the preva-
lence of CML with an important economic impact for
patients and health care systems worldwide, especially
in developing countries.4 Affording treatment is not
the only problem when economic conditions are not
ideal; accurate diagnosis and subsequent monitoring
of the disease by the detection of the Ph+ or BCR/
ABL transcript require specialized and expensive
equipment.4,5
Unfavorable circumstances are found in most devel-
oping countries, which include 80% of the world’s
population according to the United Nations. Cases
where hematologists initiate treatment taking into
account only symptoms, signs, complete blood count
and blood film findings are commonplace. In some cir-
cumstances, the hematologist is forced to use outdated
treatments such as busulfan or hydroxyurea until
access to tyrosine-kinase inhibitors (TKIs) is obtained.
Correspondence to: David Gómez-Almaguer, Servicio de Hematología del
Hospital Universitario, Universidad Autónoma de Nuevo León, Madero y
Gonzalitos Colonia Mitras Centro, C.P. 64460, Mexico.
Email: dgomezalmaguer@gmail.com
© Informa UK Limited, trading as Taylor & Francis Group 2016
DOI 10.1080/10245332.2016.1182695 Hematology 2016 1
D
ow
nl
oa
de
d 
by
 [G
uil
ler
mo
 R
uiz
 A
rg
ue
lle
s] 
at 
09
:52
 02
 Ju
ne
 20
16
 
This article describes our experience in the diagnosis
and treatment of CML in an environment that lacks
ideal resources.
Diagnosis
The combination of an elevated white blood cell count
and an enlarged spleen is very suggestive of CML. The
blood smear usually reveals eosinophilia, basophilia,
and a normal or elevated platelet count. The amount
of blasts and basophils in blood and marrow must be
determined for disease staging. Many patients are
initially treated using this simple information, but
correct diagnosis requires demonstration of Ph+
through conventional karyotyping or by fluorescent in
situ hybridization (FISH), or determination of the
BCR-ABL hybrid gene by polymerase chain reaction
(PCR) techniques.5 Good quality cytogenetic analysis
can be found in most hospitals. On the other hand,
FISH is a faster technique, which is why it is preferred
in some cases. In a Mexican institution, FISH was
found to be more useful technique compared with cyto-
genetics for initial diagnosis.6 However, in a survey run
by Latin America Leukemia Net, cytogenetics was still
the preferred method for initial diagnosis (78%),
whereas FISH was preferred by only 26% of 435
hematologists and oncologists.7 PCR is usually more
expensive and not easily available, but it is most
helpful for minimal residual disease monitoring and
should be considered a priority for optimal treatment
follow-up.5 It is noteworthy that commercial PCR kits
allow detection of common translocations but fail to
amplify rare variants (b3a3, b2a3). This can generate
false negative results and an impression of complete
molecular response (CMR) later on.8 Therefore, assess-
ment of the BCR-ABL transcript by PCR at diagnosis
is important to establish the type of fusion present.
Cytogenetics or FISH are good options for moni-
toring in places where PCR is not available. After
diagnosis patients must be staged into chronic
(CP), accelerated (AP), or blast phase (BP).9 In our
center, patients who present in AP or BP are
usually treated with imatinib and the search for a
stem cell donor is initiated. If the patient is in CP,
risk evaluation should be performed. Several risk
stratification scores have been published including
Sokal, Hasford, and EUTOS.10 We prefer the
Sokal score because only age, spleen size, platelet
count, and peripheral blast cell count are required.11
The new EUTOS score is simple, only basophil per-
centage in peripheral blood and spleen size is
Figure 1 Proposed schema for newly diagnosed CML patients treatment based on drug availability in an environment with
limited resources.
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required. It has been designed for patients treated
with imatinib, but there are doubts regarding its val-
idity.12 In a study by Jabbour et al.,13 the EUTOS
score was not predictive of outcome or survival. In
selected cases, high-risk patients could be initially
treated with higher doses of imatinib or, if available,
a second-generation TKI Figure. 1.
Monitoring
Around two thirds of CML patients will have a good
response to imatinib. In this setting, it is of great
importance to provide continuous optimal therapy,
achieve good adherence, treat common adverse
events and have adequate monitoring. When there
are multiple good quality monitoring options avail-
able, cytogenetics and PCR are the ideal methods.
Bone marrow cytogenetics is considered the ‘gold stan-
dard’, and a complete cytogenetic response is clearly
associated with improved survival. Additionally, this
method can demonstrate other chromosomal abnorm-
alities, some of which can predict resistance, an advan-
tage over FISH or PCR. Performing PCR from a
peripheral blood sample every 3–6 months, at least
for the first year, is important as long-term outcomes
can be predicted by very early responses (3 months).
For patients with BCR-ABL1> 10% IS increasing
the imatinib dose or switching to a second-generation
TKI should be considered. In the case of a young
patient (<45 years), the search for a stem cell donor
should begin when the possibility of gaining access
to a second-generation TKI is low.
In our practice, we have frequently been forced to
use FISH for monitoring. This study, correlates well
with cytogenetics, is faster and can also be performed
on a peripheral blood sample. When FISH, and/or
PCR become negative for the Ph+, we recommend
performing these studies every 6–12 months thereafter.
Because of its increased sensitivity PCR is preferable
to FISH for monitoring after achieving a complete
response. Nevertheless, FISH is an option if PCR is
not available or affordable. In a survey of 435 Latin
American hematologists/oncologists on monitoring
responses, 72% reported routinely using cytogenetics,
only 59% used PCR, 30% used mutational analysis,
and 19% used FISH. Interestingly, 13% of hematolo-
gists reported never using PCR.7 In a recent study
from the United States, Di Bella et al. analyzed mol-
ecular and cytogenetic response assessment patterns
in 300 patients who received first-line imatinib, dasati-
nib, or nilotinib in a community setting and found that
40% of patients never had any cytogenetic or molecu-
lar monitoring at any time.14
Initial treatment
Second-generation TKIs such as dasatinib or nilotinib
have been suggested as the ideal initial CML
treatment. Comparative phase III studies like
DASISION15 and ENESTnd16 have shown initial
superiority for both dasatinib and nilotinib versus
imatinib. Nevertheless, the cost of this strategy has
an important economic impact. It is essential, when
treating patients in low-income countries, to empha-
size that imatinib is highly effective as a first-line treat-
ment for CML, and according to the data of the IRIS
study, an overall survival (OS) rate of 86% was
obtained.2 Imatinib has a good safety profile, thou-
sands of patients take it daily, and in many cases
have been doing so for over 15 years. Many may com-
plain of gastrointestinal discomfort, fluid retention,
muscle cramps, and soreness, yet, in our experience
only a few will eventually discontinue treatment. In a
study that included 832 patients who had been on ima-
tinib treatment for a median of almost six years only
2.3% discontinued the drug, OS was not significantly
different from the general population and CML was
the cause of death in only six patients.17 In another
study from Italy that included 559 newly diagnosed
CP patients treated with front-line imatinib the 6-
year OS was 89% and only 5% of the patients were
considered as having a leukemia-related death.18 In
the setting of imatinib adherence, in contrast with a
British patient group with a reported adherence rate
of 97.6%,19 our experience with a group of 38 patients
receiving the drug at no cost, adherence was poor. We
found that 95% of patients had an adherence rate
below 85%. No association with age or gender was
found, however, educational level (median 8 years of
school attendance) was lower in contrast to other
studies, and this may have had an impact on these
findings.20 In this scenario, Rego et al.,21 from
Brazil, also showed that low educational level but
not low income has an impact on achieving cytoge-
netic remission.
In the ENESTnd study, nilotinib achieved a greater
cytogenetic and molecular response at a dosage of
300 or 400 mg twice a day, compared to imatinib at
400 mg daily. However, not everything favors niloti-
nib as it can cause serious vascular events and an
increase in glycemia, lipase, and hepatic
enzymes.16,22 Other aspects to consider are conven-
ience and adherence since nilotinib must be adminis-
tered twice daily and its absorption is affected by
food.16 Moreover, its cost is higher than imatinib,23
and most importantly, a survival benefit has not
been demonstrated so far.
Dasatinib is the most potent of the three most
studied TKIs.15 It can be administered once a day
without compromising efficacy, and its absorption
is not affected by food. The drug is usually well tol-
erated; however, the development of pleural effusion
and pulmonary hypertension are major concerns.24
As would be expected, these patients used more
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health-related resources and thus costs increased. The
DASISION study was designed to compare up-front
dasatinib verus imatinib. In this study dasatinib
100 mg was more effective than imatinib 400 mg
daily. Earlier molecular remissions were obtained
with a lower rate of progression. But as was the
case with nilotinib, no survival advantage was
demonstrated. Additionally, the cost of dasatinib in
Mexico is higher than both imatinib and nilotinib
(Table 1). It is noteworthy that low doses of dasatinib
have been used without compromising its efficacy.25
Since dasatinib has 100–300-fold activity compared
to imatinib, a reduced dose (50 mg per day) could
be sufficient for optimal response at cost similar to
full-dose imatinib as front-line treatment, making
this an attractive option that warrants further
investigation.
We believe that imatinib is the most cost-effective
drug for starting treatment in patients with chronic-
phase CML who are in unfavorable economic circum-
stances. Clinicians throughout the world are more fam-
iliar with this TKI, and more importantly, generic
imatinib is already available in many countries. This
will reduce the cost burden of long-term therapy. We
usually initiate imatinib at 400 mg per day Figure. 1.
However, in selected high-risk patients, unless there is
another TKI, high-dose imatinib (600–800 mg/day) is
expected to result in higher rates of complete cytoge-
netic and molecular responses.26 In a study by Cortés
et al., in 115 patients with CP-CML the MMR was
48% at six months and CMR 39%, while only 10
patients discontinued imatinib because of adverse
events.27 It is important to be aware of the economic
impact of these higher doses with the associated risk
of lower tolerance and adherence.
Generic imatinib
In Mexico the cost of one year of imatinib (Gleevec®)
is less than $30 000 USD dollars, whereas in the
United States is $92 000 USD per year. In the
United Kingdom imatinib costs $33 500 USD. In
both the United States and Mexico nilotinib and dasa-
tinib are more expensive than imatinib.28 Generic ima-
tinib is already available in several countries, and it
appears to be as effective and safe as the original
molecule. In a recent study from Turkey,29 two
groups of CML patients received the same dose of
generic or original imatinib, 400 mg per day. One
group switched from Gleevec® to generic and after a
median follow up of 63 months this group was not
inferior to the original drug group of patients in
relation to tolerance and efficacy. Similar information
has emerged from India and elsewhere.30,31 The immi-
nent availability of generic imatinib will make this
drug even more attractive to the health authorities
worldwide. Imatinib should be considered the drug
of choice at least for low risk CML patients.
Allo-HSCT in the TKI era
Therapeutic options for CML have changed in the last
12 years. The number of Allo-HSCT performed has
decreased markedly in developed countries and imati-
nib and other TKIs have replaced this procedure as
the first-line therapy for CML patients.32 However,
this is not so true for less fortunate patients living in
developing countries where imatinib and other TKIs
costs can be prohibitive. Thus, it is cheaper to
perform Allo-HSCT than to provide imatinib for
many years. In China, Mexico, Eastern Europe, and
other Latin American countries costs favor Allo-
HSCT, since this is a ‘once in a lifetime’ procedure com-
pared to lifelong therapy with a TKI.33,34 The annual
cost for imatinib in China is $41 000 USD, but econ-
omically disadvantaged patients may be eligible to
receive partial financial help from the national health
system. Nonetheless, patients are still responsible for
covering $10 300 USD per year.34 On the other hand
the cost of an Allo-HSCT is between $20 000 USD
and $30 000 USD. In a cohort of 46 Chinese patients
who underwent myeloablative Allo-HSCT with a low
EBMT risk score, the estimated probability of OS and
event free survival (EFS) was 91% after a median
follow up of 43 months.34 In Mexico a year’s worth of
imatinib costs around $21 754.00 USD compared to
Allo-HSCT at $12 000–18 000 USD if reduced inten-
sity conditioning (RIC) is employed.33,35 In our experi-
ence, 72 patientswere followed during a six-year period,
among these 50 were treatedwith TKIs and the remain-
derwere transplanted, with aprojected 90-monthOSof
84 and 77%, respectively. It is noteworthy that 21 of 22
allografted patients chose transplantation because they
were unable to afford the high cost of long-term TKI
treatment.33 The safety and effectiveness of Allo-SCT
are continually improving and thus every health care
system must consider it an option in a context of cost-
effectiveness when compared with TKI treatment.
Factors to consider in Allo-HSCT
Several factors influence patients’ outcomes after
undergoing Allo-HSCT including age, disease stage,
and treatment response; stem cell donor and source;
Table 1 Cost of CML treatment in Mexico using a tyrosine-
kinase inhibitor
Drug Dose Cost per year (USD)
Imatinib 100 mg 400 mg/day 21 754.00
600 mg/day 32 631.00
800 mg/day 43 508.00
Nilotinib 150 mg 600 mg/day 27 972.20
Dasatinib 50 mg 100 mg/day 41 318.00
Ponatinib 45 mg/day Not available in Mexico
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and type of conditioning used. In the pre-TKI era, the
major factor influencing transplantation outcomes
was disease phase at time of transplant, with patients
in advanced phase faring poorly (a fact which remains
unchanged).35 Allo-HSCT is still preferred for patients
in the more advanced phases of the disease. Imatinib
has proven EFS and OS at 6 years of 83 and 88%,
respectively,36 versus OS at 5 years in patients who
underwentAllo-HSCTranging from75 to 87%depend-
ing on the patient’s clinical condition and disease
stage.37 Patients transplanted within the first year
after diagnosis had better OS and disease-free survival,
whichmeant that earlier transplantation was favored.38
An important factor when considering transplan-
tation is age, taking into account that this disease
occurs most often in adults with a median age of 62
years. This may represent an obstacle especially if mye-
loablative conditioning schemes are used.
Nevertheless, age at diagnosis from low and middle-
income countries appears to be lower than that
found in developed countries, with a median age
ranging from 37 to 38.5 years; this may allow more
patients to be considered for Allo-HSCT.6,39
CML has been thought of as a disease with an
increased susceptibility to graft-versus-leukemia
effects, which suggests that RIC might be at least
equal to myeloablative conditioning as it is associated
with a lower TRM.33,40 Other benefits exist when
using RIC, including the possibility of outpatient man-
agement, fewer hospitalizations and reduced costs,
making it an attractive option for developing
countries. In a study by Or et al.40 OS was 85% at 5
years using this strategy.
Allografting must be considered not only as salvage
treatment in advanced disease stages, but also as a
valid early treatment alternative for young selected
patients without access to long-term TKI therapy.
Our results show an OS equal to that observed in
our patients treated with TKI. Despite that the inci-
dence of acute and chronic graft versus host disease
is around 50% (Table 2) its most severe form is less fre-
quent. It is worth mentioning that 10% of patients
experience grade II–IV aGVHD and 8% have
extensive cGVHD.41–42 Finally, another important
issue to consider is quality of life, in a recent Chinese
study it was concluded that long-term CML-CP survi-
vors receiving allo-SCT can attain desirable quality of
life comparable to or better than that of patients
receiving imatinib.34
TKI treatment expectations
Imatinib and the new TKIs are capable of long-term
leukemic control or molecular remission in the
majority of CML patients; however, lifelong treatment
is considered to be necessary. International guidelines
recommend indefinite continuation of TKI treatment
in all responding patients. The cost of many years of
imatinib treatment is substantial. In Mexico 20 years
worth of imatinib is around $435 000 USD.
Therefore, the possibility of stopping therapy without
serious risk of transformation/complications in an
expensive chronic disease is appealing, especially in
an economic environment with limited health
resources. In the French Stop Imatinib trial (STIM)
in 100 patients, 41% were still in CMR after a 12
month follow-up, moreover, all patients who relapsed
responded again to imatinib. It was concluded that
imatinib can be safely interrupted in patients with a
CMR of at least 2 years.43 In a recent evidence-based
mini review presented at the American Society of
Hematology meeting in 2013, seven prospective and
two retrospective trials were analyzed; it was con-
cluded that selected patients, perhaps half of them,
may remain treatment-free for a long period of
time.44 The information in relation to dasatinib and
noilotinib discontinuation in CML-CP is limited,45
but since these drugs are more potent than imatinib
and capable of producing higher CMR rates, it is
reasonable to expect similar or better long-term
results after discontinuation of these second-gener-
ation TKI. We can assume that cure is possible in a
subset of CML patients, but further identification of
this subgroup is necessary. In our institution we are
now halting imatinib in selected patients who have
been in CMR for more than 2 years. Therefore, the
availability of PCR is crucial for this purpose and it
Table 2 Comparison of two treatment options in patients with CML: Allo-HSCT verus TKI
Trial ID n=
Treatment received
(n = ) Age (median) OS% PFS%
Ruiz-Argüelles et al. 72 Allo-HSCT 22 38 77 (6y) NA
TKI 50 39 84 (6y) NA
Qian Jiang et al. 132 AP Allo-HSCT 45 34 83.3 (6y) 92.5 (6y)
Imatinib 87 44 51.4 (6y) 48.3 (6y)
Xu et al. 93 AP Allo-HSCT 60 NA 86.4 (5 y) 78.1 (5y)
TKI 33 NA 42.9 (5y) 28.6 (5y)
Hamidieh et al. 33 Allo-HSCT 14 12.8 84 (2y) 59 (2y)
Imatinib 19 9.5 87 (2y) 82 (2y)
Allo-SCT, allogeneic stem cell transplantation; TKI, tyrosine-kinase inhibitor; AP, accelerated phase; OS, overall survival; PFS,
progression free survival; aGvHD, acute graft versus host disease; cGvHD, chronic graft versus host disease.
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is also very important for after-therapy monitoring.
This practice should become more frequent in
countries where the resources for long-term TKI
therapy are not available.
Summary
The majority of CML patients in the developing world
do not have easy access to long-term TKI treatment.
Until last year, thousands of patients living in low and
middle-income countries were treated using free-of-
charge imatinib provided by the Gleevec International
Patient Assistance Program initiative (GIPAP).46
With the end of this program (March 2015), forced by
the worldwide arrival of the generic drug, many
patients will require new therapeutic strategies.
Hematologists working in a limited-resource
environment must be creative. The use of generic ima-
tinib must be weighed against the option of early Allo-
HSCT in patients with a compatible donor if long-
term TKI treatment is unavailable.3 Another strategy
that should be considered is TKI discontinuation in
patients who meet the selection criteria. All of these
considerations should be taken into account not only
to decide the treatment of an individual patient, but
also to design and implement healthcare policies in
the developing world.
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